Intravitreal dexamethasone as an enhancer for the anti-VEGF treatment in neovascular ARMD: Recovering an old ally;Dexametasona intravítrea como potenciador del tratamiento anti-VEGF en la degeneración macular asociada a la edad neovascular: recuperando un viejo aliado

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 85, Issue 2, 2010, Pages 79-80

  Gallego Pinazo, R ^a   Marin Lambies C ^a   Marin Olmos F ^b   Martinez R ^b   Fons, R ^c   Diaz Llopis M L ^a,d,e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL LLUÍS ALCANYÍS   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; VASCULOTROPIN A;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; LETTER; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL NEOVASCULARIZATION;

CHOROIDAL NEOVASCULARIZATION; DEXAMETHASONE; HUMANS; INTRAVITREAL INJECTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 77955683833     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0365-6691(10)70020-4     Document Type: Letter

References (3)

1. S.J. Bakri, S.M. Couch, C.A. McCannel, and A.O. Edwards Same-day triple therapy with hotodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration Retina. 29 2009 573 578
2. R.O. Graham, and G.A. Peyman Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis Arch Ophthalmol. 92 1974 149 154
3. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung, S.R. Dubovy, S. Michels, and W. Feuer A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol. 148 2009 43 58